Andrew T. Kuykendall, MD
Drug development in myeloproliferative neoplasms (MPNs), specifically polycythemia vera (PV) and myelofibrosis, have both remained similar to their diagnosis: difficult, explained Andrew T. Kuykendall, MD.
on Hematologic Malignancies, Kuykendall discussed the presentation of these neoplasms, novel agents in development, and the overall outlook of these diseases.
OncLive®: How do these neoplasms typically present?
: The first challenge with diagnosing PV is ruling out primary PV from other causes that lead to erythrocytosis. The JAK mutation has been extremely helpful because it identifies patients who have this disease. The new World Health Organization criteria has relaxed the hemoglobin thresholds that we used to have, so that has allowed us to capture an increased volume of patients who otherwise weren't meeting the criteria.
Myelofibrosis is a more difficult challenge. Myelofibrosis is largely diagnosed off the bone marrow biopsy. It can present in any number of ways with thrombocytosis, erythrocytosis, or leukocytosis. It can present with cytopenias and relatively normal blood counts, but a lot of symptoms and splenomegaly. It's different for every patient, and so we normally go based on the bone marrow morphology. Next-generation sequencing has helped us to some degree to identify driver mutations in addition to cooperating mutations that we know occur more often in these diseases.
How have novel agents impacted the field?
Ruxolitinib has had a huge impact across the MPN field. It's an intelligently designed drug that acts on the JAK-STAT pathway, which we know is hyperactive in all of these conditions. In myelofibrosis, it has probably made the biggest change in how we approach the disease. It’s allowed patients who are incredibly symptomatic to be resolved of their symptoms and go back to feeling normal. This wasn't previously possible. We're still trying to understand how much it's revolutionized the landscape as far as how it's improving transplant outcomes, why we're seeing survival benefits, etc.
... to read the full story